New insights into PARP inhibitors' effect on cell cycle and homology-directed DNA damage repair.

@article{Jelinic2014NewII,
  title={New insights into PARP inhibitors' effect on cell cycle and homology-directed DNA damage repair.},
  author={Petar Jelinic and Douglas A. Levine},
  journal={Molecular cancer therapeutics},
  year={2014},
  volume={13 6},
  pages={1645-54}
}
In preclinical and clinical studies, olaparib and veliparib are the most represented PARP inhibitors (PARPi), which mainly target homologous DNA damage repair pathway-deficient cancer cells. Their off-target effects are not fully understood, especially with regard to cell cycle and homology-directed DNA damage repair. Our objective was to comparatively evaluate olaparib and veliparib in this context and correlate our findings with their therapeutic potential. We used a well-established direct… CONTINUE READING